News | Prostate Cancer | October 17, 2018

SpaceOAR Hydrogel System for prostate positioning during radiotherapy joins Boston Scientific’s prostate health portfolio

Boston Scientific Closes Acquisition of Augmenix Inc.

October 17, 2018 — Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The biodegradable SpaceOAR hydrogel is injected between the rectum and prostate to decrease a patient's exposure to rectal radiation and thereby reduce rectal radiation injury – one of the most common complications of prostate radiotherapy.

The close marks the third completed acquisition in 2018 for Boston Scientific’s Urology and Pelvic Health portfolio. The SpaceOAR Hydrogel System will expand the company’s prostate health portfolio, which includes therapies to treat benign prostatic hyperplasia, including the Rezūm System, the GreenLight XPS Laser Therapy System and holmium laser platforms.

Boston Scientific announced a definitive agreement to acquire Augmenix on Sept. 6, 2018 for $500 million in up-front cash and up to $100 million for reaching sales-based milestones.

For more information: www.bostonscientific.com


Related Content

News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | Radiation Oncology

September 13, 2023 — Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients ...

Time September 13, 2023
arrow
News | Radiation Oncology

September 12, 2023 — Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining NYU Langone’s ...

Time September 12, 2023
arrow
News | Ultrasound Imaging

September 8, 2023 — When diagnosing and treating cancer patients, the dynamics of blood flow to and from a suspected ...

Time September 08, 2023
arrow
News | Radiation Oncology

September 6, 2023 — Nina D’Abreo, MD, has been named as chief of the Division of Hematology and Medical Oncology at NYU ...

Time September 06, 2023
arrow
News | Radiation Oncology

August 30, 2023 — Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including ...

Time August 30, 2023
arrow
News | Radiation Therapy

August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children ...

Time August 30, 2023
arrow
Subscribe Now